8-K current report · filed Oct 26, 2026

Phathom Pharmaceuticals, Inc. (PHAT) 8-K Current Report: October 26, 2026

Item 8.01PHAT overview

Short answer

Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events). FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026.

Phathom Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026
  • BDR challenges FDA’s recognition of VOQUEZNA’s NCE exclusivity through May 3, 2032
  • Adverse FDA or court action could accelerate generic ANDA review and VOQUEZNA competition
  • Saba Ilac intends to consolidate a related case with BDR’s litigation, broadening competitive risk
  • Phathom plans FDA comments and litigation participation to defend exclusivity and future VOQUEZNA sales

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Phathom Pharmaceuticals, Inc. 8-K filings

Get the next PHAT 8-K as it lands

Follow PHAT for push alerts, or ask the research agent what this filing means.